Byrnes V, Afdhal N, Challies T, Greenstein PE

Language: English
References: 7
Page: 56-59
PDF size: 160.34 Kb.

Text Extraction

Post marketing studies of Interferon-β (IFNβ) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of hepatotoxicity. Grade 3 hepatotoxicity (AST and ALT › 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on IFNβ. We report three cases of IFNβ induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.

REFERENCES

1. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology 2004; 62: 628-631.

2. Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler 2004; 10: 298-301.

3. Francis GS, Grumser Y, Alteri E, Micaleff A, O’Brien F, Alsop J, Stam Moraga M, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003; 26: 815-827.

4. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-176.

5. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485.

6. Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998; 50: 570-571.

7. Speciale L, Saresella M, Caputo D, Ruzzante S, Mancuso R, Calvo MG, Guerini FR, et al. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J Neurovirol 2000; 6 Suppl 2: S57-61.